ESC 365 - SGLT2 inhibition: the potential to change the heart failure landscape?

Open Access

SGLT2 inhibition: the potential to change the heart failure landscape?

Session: Challenging the current treatment paradigm - SGLT2 inhibition in heart failure (EBAC Accredited)

Topic: Antiarrhythmic drugs

Speaker: Professor J. McMurray (Glasgow, GB)

Sponsored by AstraZeneca

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

127 presentations

26 followers

4 more presentations in this session

Chair’s introduction - Challenging the current treatment paradigm - SGLT2 inhibition in heart failure.

Speaker: Professor M. Metra (Brescia, IT)

The ongoing problem of heart failure.

Speaker: Professor K. Ray (London, GB)

Q&A - Challenging the current treatment paradigm - SGLT2 inhibition in heart failure.

Speaker: Professor M. Metra (Brescia, IT) Professor K. Ray (London, GB)

Summary & close - Challenging the current treatment paradigm - SGLT2 inhibition in heart failure.

Speaker: Professor M. Metra (Brescia, IT)

Access the full session

Challenging the current treatment paradigm - SGLT2 inhibition in heart failure (EBAC Accredited)

Speakers: Professor J. McMurray, Professor M. Metra, Professor K. Ray, Professor M. Metra, Professor K. Ray...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources